Odum N, Morling N, Platz P, Hofmann B, Ryder L P, Heilmann C, Pedersen F K, Nielsen L P, Friis J, Svejgaard A
Department of Clinical Immunology, State University Hospital (Rigshospitalet), Copenhagen, Denmark.
Ann Rheum Dis. 1987 Nov;46(11):846-52. doi: 10.1136/ard.46.11.846.
The presence of activated T cells as judged from the reaction with monoclonal antibodies (MoAb) against (a) a late stage T cell activation antigen (VLA-1), (b) the interleukin 2 (IL2) receptor (CD25), and (c) four different HLA class II molecules (HLA-DR, DRw52, DQ, and DP) was studied in 15 patients with active juvenile chronic arthritis (JCA), 10 patients with JCA in remission, and 11 age matched, healthy controls. In addition, the distribution of T 'helper/inducer' (CD4+), T 'suppressor/inducer' (CD4+, Leu8+), T 'suppressor/cytotoxic' (CD8+), and 'natural killer' (NK) cells (CD16+) was studied. Twenty patients and six controls were investigated for the capability to stimulate alloreactivated primed lymphocytes. The prevalence of VLA-1 positive, large cells was significantly increased to 5% (median value) in active JCA as compared with JCA in remission (2%, p less than 0.05) and controls (1%, p less than 0.05), whereas no significant difference between JCA in remission and controls was observed. Except for two patients with active JCA, less than 1% IL2 receptor bearing cells were found in patients with JCA and controls. No significant difference in the prevalence and expression of the various HLA class II antigens was observed between the groups. Similarly, no significant differences in stimulatory capability in secondary mixed lymphocyte culture (MLC) were seen. The distribution of T helper/inducer (CD4+), T suppressor/cytotoxic (CD8+), and NK cells was similar in active JCA, JCA in remission, and controls. The prevalence of T suppressor/inducer (CD4+,Leu8+) cells was higher in remission JCA (17%) than in active JCA (11%) and controls (10%). This increase, however, did not reach statistical significance. In conclusion, late stage but not early stage T cell activation antigens were increased in patients with active JCA as compared with patients with JCA in remission and control, whereas some patients in remission had an increased prevalence of T suppressor/inducer cells.
通过与针对以下几种物质的单克隆抗体(MoAb)反应来判断活化T细胞的存在情况:(a)一种晚期T细胞活化抗原(VLA-1);(b)白细胞介素2(IL2)受体(CD25);(c)四种不同的HLA-II类分子(HLA-DR、DRw52、DQ和DP)。对15例活动性幼年慢性关节炎(JCA)患者、10例缓解期JCA患者以及11名年龄匹配的健康对照者进行了研究。此外,还研究了T“辅助/诱导”(CD4+)、T“抑制/诱导”(CD4+、Leu8+)、T“抑制/细胞毒性”(CD8+)和“自然杀伤”(NK)细胞(CD16+)的分布情况。对20例患者和6名对照者进行了刺激同种异体活化致敏淋巴细胞能力的研究。与缓解期JCA(2%,p<0.05)和对照者(1%,p<0.05)相比,活动性JCA中VLA-1阳性大细胞的患病率显著增加至5%(中位数),而缓解期JCA与对照者之间未观察到显著差异。除2例活动性JCA患者外,JCA患者和对照者中携带IL2受体的细胞不到1%。各组之间在各种HLA-II类抗原的患病率和表达方面未观察到显著差异。同样,在二次混合淋巴细胞培养(MLC)中的刺激能力也未观察到显著差异。活动性JCA、缓解期JCA患者和对照者中T辅助/诱导(CD4+)、T抑制/细胞毒性(CD8+)和NK细胞的分布相似。缓解期JCA中T抑制/诱导(CD4+、Leu8+)细胞的患病率(17%)高于活动性JCA(11%)和对照者(10%)。然而,这种增加未达到统计学显著性。总之,与缓解期JCA患者和对照者相比,活动性JCA患者晚期而非早期T细胞活化抗原增加,而一些缓解期患者中T抑制/诱导细胞的患病率增加。